Ora Pharm has acquired the manufacturing assets of failed medicinal cannabis company Helius Therapeutics, establishing the largest end-to-end supply chain in New Zealand’s medicinal cannabis sector. Following Helius Therapeutics’ entry into voluntary administration and the closure of its Auckland plant in March due to trading losses, Ora Pharm confirmed the purchase for an undisclosed sum. The move allows Ora Pharm to immediately scale its production capabilities while integrating its existing grower network with the newly acquired infrastructure.
How does the acquisition change the New Zealand cannabis market?
The deal positions Ora Pharm as the dominant player in the local medicinal cannabis industry. According to Ora Pharm CEO Zoe Reece, the acquisition fills a critical gap in the company’s operations, as it had previously planned to build its own facility. By purchasing the Helius plant, the company has bypassed the construction phase to begin immediate manufacturing. This consolidation follows a period of financial instability for several industry start-ups, marking a shift toward more integrated business models to ensure long-term viability.
Before the sale, Helius Therapeutics shuttered its operations citing high operating costs and a demanding regulatory landscape as the primary drivers of its trading losses.
Why is the regulatory environment considered a factor in industry success?
New Zealand’s medicinal cannabis regulations are stringent, requiring manufacturers to meet high pharmaceutical standards. While some firms have struggled with these costs, Ora Pharm’s leadership views the oversight as a necessary component of patient safety. Zoe Reece, who previously worked in the United States, noted that New Zealand’s framework is highly structured compared to the fragmented, state-by-state regulations she encountered abroad. She emphasized that because these products are medicine, they must adhere to the same rigorous testing and quality assurance protocols as any other pharmaceutical drug.
Pro Tip: Navigating Industry Compliance
For companies in the pharmaceutical space, compliance is not just a hurdle but a foundation for market trust. Ora Pharm’s ability to secure new licenses following the Helius purchase highlights the importance of having a clear regulatory strategy before expanding infrastructure.
What are the future trends for medicinal cannabis supply chains?
Industry experts suggest a move toward shared infrastructure and regional hubs to mitigate the high costs that led to the collapse of companies like Helius. According to Ora Pharm, the future of the sector relies on moving away from isolated operations. By building common infrastructure for growers, companies can achieve greater efficiency and improve the quality of supply. This integrated approach is intended to strengthen New Zealand’s position on the global stage, allowing for a more robust export and domestic supply chain.
Frequently Asked Questions
- Who purchased Helius Therapeutics’ assets? Ora Pharm acquired the business and its Auckland manufacturing plant.
- Why did Helius Therapeutics fail? The company entered voluntary administration in March due to continuing trading losses, high operating costs, and a challenging regulatory environment.
- Will product supply be affected? Ora Pharm stated it intends to resume the supply of medicinal cannabis products to patients shortly.
- What happens to Helius staff? Ora Pharm reported that it retained a small number of key manufacturing staff, while the remaining roles were filled by its existing workforce.
Are you interested in the latest developments in the pharmaceutical and biotech sectors? Subscribe to our newsletter for expert analysis and industry updates delivered directly to your inbox.
